Načítá se...

Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma: systematic review and meta-analysis of 14 trials

OBJECTIVE: Carfilzomib (Carf) is a second-generation proteasome inhibitor approved for patients with relapsed and/or refractory multiple myeloma (RRMM) who failed ≥ 1 prior lines of therapy. We performed a systematic review of Carf literature with meta-analysis to determine the efficacy and safety i...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Shah, Chintan, Bishnoi, Rohit, Wang, Yu, Zou, Fei, Bejjanki, Harini, Master, Samip, Moreb, Jan S.
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2018
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5955098/
https://ncbi.nlm.nih.gov/pubmed/29805768
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25281
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!